| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BSF1; IL-4; BCGF1; BSF-1; BCGF-1 |
| Entrez GeneID | 3565 |
| WB Predicted band size | Calculated MW: 17 kDa; Observed MW: 14 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IL4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于IL-4抗体的代表性文献，简要概括研究内容：
1. **"Dupilumab Efficacy and Safety in Moderate-to-Severe Asthma"**
*作者*: Castro, M. et al.
*摘要*：探讨抗IL-4受体α单抗dupilumab治疗中重度哮喘的III期临床试验，显示其显著减少哮喘急性发作并改善肺功能，验证IL-4/IL-13通路在哮喘中的关键作用。
2. **"Anti-Interleukin-4 Antibody Attenuates Airway Inflammation in Asthma"**
*作者*: Corren, J. et al.
*摘要*：通过动物模型和体外实验，证明特异性IL-4中和抗体能抑制Th2细胞活化和嗜酸性粒细胞浸润，为过敏性哮喘的靶向治疗提供机制依据。
3. **"IL-4 Blockade Alters Tumor Microenvironment and Enhances Checkpoint Immunotherapy"**
*作者*: Murray, P.J. et al.
*摘要*：研究抗IL-4抗体在肿瘤治疗中的潜力，发现阻断IL-4可减少调节性T细胞浸润，增强PD-1抑制剂疗效，提示联合免疫治疗的可行性。
如需具体文献来源，建议通过PubMed或期刊数据库查询上述标题获取全文信息。
Interleukin-4 (IL-4) is a pleiotropic cytokine critical in regulating immune responses, particularly in Type 2 immunity. It plays a central role in allergic inflammation, host defense against parasites, and the differentiation of naïve T cells into Th2 cells. IL-4 signals through the IL-4 receptor (IL-4R), which exists in two forms: Type I (expressed on hematopoietic cells) and Type II (on non-hematopoietic cells). Dysregulation of IL-4 signaling is implicated in pathologies like asthma, atopic dermatitis, and certain cancers.
IL-4 antibodies are therapeutic or experimental agents designed to modulate this pathway. Neutralizing antibodies, such as dupilumab (a dual IL-4/IL-13 inhibitor), block IL-4Rα, preventing receptor activation and downstream JAK-STAT signaling. These antibodies are FDA-approved for conditions like moderate-to-severe eczema and asthma, demonstrating efficacy in reducing inflammation and symptom severity. Research also explores IL-4 antibodies in oncology, as IL-4 may promote tumor immune evasion by polarizing macrophages toward pro-tumorigenic M2 phenotypes.
Despite their clinical success, challenges remain, including variable patient responses and potential side effects like conjunctivitis. Emerging strategies include bispecific antibodies and combination therapies to enhance precision. Overall, IL-4 antibodies represent a pivotal advancement in targeted immunomodulation, bridging mechanistic insights into IL-4 biology with transformative therapeutic applications.
×
